The Primary Care Respiratory Society

Inspiring best practice in respiratory care

This website is for healthcare professionals only



The Primary Care Respiratory Society

Inspiring best practice in respiratory care

Facebook LogoTwitter Logo  Login

This website is for healthcare professionals only

Asthma Right Care Resources

ARC Banner

Be a part of our #AsthmaMyths Campaign

Watch our animations and listen to our podcast series (click on the links below): these highlight some of the more common myths that can form a barrier to effective symptom control.  Read about this issue in more depth.

PCRS has guidance and resources to help you support your patients and blow away common myths associated with asthma and improve patient outcomes.

You can do a lot in practice to help people live better with asthma. The time you invest and the words you use really do matter to promote ‘self care’ as myths still exist that can be countered with the right clinical skills and resources to aid.

Myth #1 "Asthma Is Not a Serious Disease"

Myth #2 "Coughing is part and parcel of asthma"

"It’s only asthma...” Sound familiar? Many patients wrongly think asthma is not a serious disease.

Find out more ...

The truth is with the right treatment patients with asthma can lead a normal life.

Find out more ...

Coughing is part and parcel of asthma

Myth #3 "I only need my blue inhaler"

Myth #4 “I’m just allergic to some things...otherwise I’m ok”

The truth is people with asthma need to carry their blue inhaler for emergencies only. Daily preventers will keep symptoms at bay.

Find out more ...

The truth is avoiding 'triggers' can reduce symptoms and taking a blue inhaler, can help to provide short-term relief but they don’t address the underlying problem - inflammation.

Find out more...

Asthma triggers


Other Asthma Right Care (ARC) Resources

The nine processes to achieve ARC

Practice and Pharmacy Posters

9 Processes Image

In this article for Primary Care Respiratory Academy, Noel Baxter describes the 9 good care processes developed by a multidisciplinary and integrated respiratory team in Lambeth and Southwark with a novel way to disseminate the measures and show improvement.


PCRS offer two posters available for download and use in practice surgeries and pharmacies. The posters highlight the benefit of regular preventer inhaler therapy and a reduction in reliance on short -acting reliever inhalers. Both posters recommend talking to the practice nurse or pharmacist if patients feel they are reliant on their reliever inhaler more than three times per week of if asthma symptoms are frequent.

ARC Playing Cards

Building Blocks of a Good Asthma Review

A set of playing cards (on slides and downloadable PDF) can be a way to trigger conversations with healthcare teams, and between pharmacists and patients regarding the use of/reliance on SABA inhalers  

In this article first published in Primary Care Respiratory Update in 2016 as a poster for primary care and updated for asthma in November 2019 we discuss the building blocks of a good asthma review focusing on:

  • Assessing control to target care
  • Reviewing diagnosis and management
  • Confirmation of  diagnosis
  • Previous medical history
  • Patient understanding
  • Checking inhaler technique
  • Discussing and reviewing adherence to therapy
  • Checking smoking status and offering appropriate smoking cessation advice where appropriate
  • Reviewing lifestyle and asthma triggers
  • Reviewing other conconitant conditions
  • Reviewing treatment in line with national guidance
  • Reviewing and discussing asthma action plan
  • Tailoring asthma action plan to meet patient's needs and setting agreed goals
  • Utilising Asthma Right Care tools to assess reliance on short-acting beta-2-agonsts 


Trudell Medical UK Limited

PCRS is grateful to Trudell Medical UK Limited for their support of the Asthma Right Care programme in 2022.

The Asthma Right Care initiative was originated by the IPCRG with funding from AstraZeneca internationally. The adaptation of materials by PCRS for use in the UK has been funded by AstraZeneca UK Limited.